



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Spike Protein of SARS-CoV-2 (COVID-19)

CATALOG NUMBER: SCV2-S-050P, 50 µg, 1 mg

Introduction

The novel coronavirus (SARS-CoV-2), previously called 2019-nCoV, is a newly identified coronavirus causing the ongoing outbreak of atypical pneumonia in Wuhan China from late 2019.

The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleocapsid protein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RBD) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.

Applications

Western blot standard, antibody ELISA, antigen, etc.

Description

Recombinant spike (aa 16-1208) protein of SARS-CoV-2 (COVID-19) purified from HEK293 cells

Viral Protein

Spike protein (amino acid 16-1208) of human SARS-CoV-2 (GenBank Accession No. QIC53204) with a C-terminal His-tag

Storage

Store at -20 °C; Stable for 6-months from the date of shipment when kept at 4 °C. Non-hazardous, no MSDS required.

Concentration


1 µg/µl in PBS, pH7.4

Endotoxin Level

<1 EU per 1 µg of the protein by LAL test

Purity

≥ 95% (by SDS PAGE)



SDS-PAGE (4-20%): purified full-length spike (aa 16-1208) protein (SARS-CoV-2)

Spike Protein (aa 16-1208)(SARS-CoV-2/COVID-19) SEQ:

VNLTTRTQLP PAYTNSFTRG VYYPDKVFRS SVLHSTQDLF LPFFSNVTWF HAIHVSGTNG TKRFDNPVLP FNDGVYFAST EKSNIIRGWI
FGTTLDSTQ SLLIVNNATN VVIKVCEQF CNDPFLGVYY HKNNKSWMES EFRVYSSANN CTFEYVSQPF LMDLEGKQGN FKNLREFVFK
NIDGYFKIYS KHTPINLVRD LPQGFSALEP LVDLPIGINI TRFQTLLALH RSYLTPGDSS SGWTAGAAAY YVGYLQPRTF LLKYNENGTI
TDAVDCALDP LSETKCTLKS FTVEKGIYQT SNFRVQPTES IVRFPNITNL CPFGEVFNAT RFASVYAWNR KRISNCVADY SVLYNSASF
TFKCYGVSP T KLNDLCFTNV YADSFVIRGD EVRQIAPGQT GKIADYNYKL PDDFTGCVIA WNSNNLDSKV GGNYNLYRL FRKSNLKPFE
RDISTEIYQA GSTPCNGVEG FNCYFPLQSY GFQPTNGVGY QPYRVVLSF ELLHAPATVC GPKKSTNLVK NKCWNFNFN LGTGVLTES
NKKFLPFQOF GRDIADTTDA VRDPQTLEIL DITPCSFGGV SVITPGTNTS NQVAVLYQDV NCTEVPVAIH ADQLTPTWRV YSTGSNVFQT
RAGCLIGA EH VNNSYEC DIP IGAGICASYQ TQTNSPRRAR SVASQSIIAY TMSLGAENSV AYSNNSIAIP TNFTISVTTE ILPVSMKTTS
VDCTMYICGD STECSNLLLQ YGSFCTQLNR ALTGIAVEQD KNTQEVFAQV KQIYKTPPIK DCGGFNFSQI LPDPSKPSKR SFIEDLLFNK
VTLADAGFIK QYGDCLGDIA ARDLICAQKF NGLTVLPPLL TDEMIAQYTS ALLAGTITSG WTFGAGAAALQ IPFAMQMAYR FNGIGVTQNV
LYENQKLIAN QFNSAIGKI Q DSLSTASAL GKLQDVVNQN AQALNTLVKQ LSSNFGAISS VLNDILSRLD KVEAEVQIDR LITGRLQSLQ
TYVTQQLIRA AEIRASANLA ATKMSECVLG QSKRVDFCGK GYHLMSFPQS APHGTVFLHV TYVPAQEKNF TTAPAICH DG KAHFPREGVF
VSNGTHWFVT QRNFYEPQII TTDNTFVSGN CDVVIGIVNN TVYDPLQPEL DSFKEELDKY FKNHTSPD VD LGDISGINAS VVNIQKEIDR
LNEVAKNLNE SLIDLQELGK YEQH HHHHHH

